VDPHL01
Phase 3Small molecule
VDPHL01 is one of 27 small molecule programs targeting Androgenetic Alopecia. It is currently in Phase 3.
1
Indications
4
Total Trials
4
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Androgenetic Alopecia
#DrugCompanyPhaseTrials
1Rogaine
PfizerApproved
Aldactone
PfizerApproved
Depakote
AbbVieApproved
Avodart
Akero TherapeuticsPhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
XEOMIN
MMerz Pharmaceuticals GmbH
Phase 2
Zolymbus
AbbViePhase 1
Platelet Rich Plasma
ZZagazig University
Phase 2
AS101
BBioMAS Ltd
Phase 2
Stem Cells
KKang Stem Biotech Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Safety and Efficacy2 trials
Androgenetic Alopecia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VDPHL01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VVeradermics, Inc.